Fusion of the genes WWTR1 and FosB in pseudomyogenic hemangioendothelioma

41Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Pseudomyogenic hemangioendothelioma is a rare endothelial tumor. Previous genetic investigations have shown that the tumors carry either a SERPINE1-FOSB or an ACTB-FOSB fusion gene. The aim of the study was to identify FOSB fusions linked with pseudomyogenic hemangioendothelioma. Materials and Methods: RNA sequencing, reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing analyses were performed on a pseudomyogenic hemangioendothelioma. Results: An in-frame fusion was found between exon 4 of WWTR1 from 3q25 and exon 2 of FOSB from 19q13. The fusion gene not only places FOSB under the control of the WWTR1 promoter, but is predicted to encode a chimeric WWTR1-FOSB transcription factor. Conclusion: FOSB may be fused with SERPINE1, ACTB, or WWTR1 in pseudomyogenic hemangioendotheliomas. The resulting overexpression of FOSB fusion is a potentially useful marker that could be helpful in the diagnosis of these tumors.

Cite

CITATION STYLE

APA

Panagopoulos, I., Lobmaier, I., Gorunova, L., & Heim, S. (2019). Fusion of the genes WWTR1 and FosB in pseudomyogenic hemangioendothelioma. Cancer Genomics and Proteomics, 16(4), 293–298. https://doi.org/10.21873/cgp.20134

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free